BSP - Biological Signal Processing Ltd. (TASE:BSP) has received a letter of intent from Swiss medical device manufacturer Schiller AG, which wants to incorporate BSP monitors in its EKG systems.
BSP and Schiller have not yet agreed on terms, and it is not certain that BSP will accept the offer. BSP CEO Amir Beker said, "When we have the letter of intent in hand, we'll contact other companies and see whether it's worthwhile for us to share exclusivity with a number of companies, in order to ensure that we get the best value for our flagship product."
EKG's are no longer considered the best diagnostic tools for heart disease. BSP says that its software can better interpret signals than the EKG, thereby enabling better diagnosis of ischemic heart diseases.
BSP recently conducted a trial of its product with Maccabi Health Services, which showed that BSP's product had an 88% correct diagnosis rate, compared with 56% for the EKG. The company aims to achieve a level of diagnosis that will enable doctors to dispense with the EKG altogether and eliminate the need to send patients for more invasive and expensive tests. The US Food and Drug Administration (FDA) has approved BSP's second-generation device.
Published by Globes [online], Israel business news - www.globes-online.com - on December 18, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007